Editorial: effectiveness and safety of vedolizumab in a matched cohort of elderly and non-elderly patients with inflammatory bowel disease-the IG-IBD LIVE study. Authors' reply

Daniela Pugliese¹, Giuseppe Privitera², Alessandro Armuzzi^{3

4}

Affiliations

¹ CEMAD - IBD UNIT, Unità Operativa Complessa di Medicina Interna e Gastroenterologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
² Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
³ IBD Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
⁴ Department of Biomedical Sciences, Humanitas University, Milan, Italy.

Editorial

Daniela Pugliese et al. Aliment Pharmacol Ther. 2022 Aug.

. 2022 Aug;56(4):733-734.

doi: 10.1111/apt.17076.

Daniela Pugliese¹, Giuseppe Privitera², Alessandro Armuzzi^{3

4}

¹ CEMAD - IBD UNIT, Unità Operativa Complessa di Medicina Interna e Gastroenterologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
² Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
³ IBD Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
⁴ Department of Biomedical Sciences, Humanitas University, Milan, Italy.

No abstract available

Comment on

Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study.
Pugliese D, Privitera G, Crispino F, Mezzina N, Castiglione F, Fiorino G, Laterza L, Viola A, Bertani L, Caprioli F, Cappello M, Barberio B, Ricci C, Balestrieri P, Daperno M, Pluchino D, Rizzello F, Scribano ML, Sablich R, Pastorelli L, Manguso F, Variola A, Di Sario A, Grossi L, Armuzzi A; IG‐IBD LIVE Study Group. Pugliese D, et al. Aliment Pharmacol Ther. 2022 Jul;56(1):95-109. doi: 10.1111/apt.16923. Epub 2022 May 12. Aliment Pharmacol Ther. 2022. PMID: 35876062 Free PMC article.
Editorial: effectiveness and safety of vedolizumab in a matched cohort of elderly and non-elderly patients with inflammatory bowel disease - the IG-IBD LIVE study.
Lee H, Khan N. Lee H, et al. Aliment Pharmacol Ther. 2022 Aug;56(4):731-732. doi: 10.1111/apt.16957. Aliment Pharmacol Ther. 2022. PMID: 35879894 No abstract available.

1. Pugliese D, Privitera G, Crispino F, Mezzina N, Castiglione F, Fiorino G, et al. Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study. Aliment Pharmacol Ther. 2022;56:95-109.
1. Lee H, Khan N. Editorial: effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease - the IG-IBD LIVE study. Aliment Pharmacol Ther. 2022;56:729-730.
1. Dulai PS, Singh S, Jiang X, et al. The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn's disease: results from the US VICTORY consortium. Am J Gastroenterol. 2016;111(8):1147-55. https://doi.org/10.1038/ajg.2016.236
1. Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, et al. Vedolizumab for ulcerative colitis: treatment outcomes from the VICTORY consortium. Am J Gastroenterol. 2018;113(9):1345. https://doi.org/10.1038/s41395-018-0162-0
1. Sands BE, Van Assche G, Tudor D, Akhundova-Unadkat G, Curtis RI, Tan T. Vedolizumab in combination with corticosteroids for induction therapy in Crohn's disease: a post hoc analysis of GEMINI 2 and 3. Inflamm Bowel Dis. 2019;25(8):1375-82. https://doi.org/10.1093/ibd/izy384